Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Atea Pharmaceuticals (Nasdaq: AVIR) will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026 at 7:30 a.m. PT in San Francisco.
Jean-Pierre Sommadossi, PhD, CEO and founder, and other Atea management will present. A live webcast will be available on the company's investor site at https://ir.ateapharma.com, with an archived webcast available for at least 90 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, AVIR declined NaN%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: NMRA -11.14%, OMER -5.93%, RAPT -6.17%, CADL -3.28%, IVVD +1.59%, suggesting AVIR’s modest -2.01% move is more stock-specific than a broad sector swing.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 22 | Phase 3 enrollment | Positive | +1.0% | Completed Phase 3 C‑BEYOND enrollment with >880 HCV patients in North America. |
| Nov 25 | Leadership update | Neutral | +1.7% | Board-level leadership change at related company highlighting Atea board role. |
| Nov 19 | Conference participation | Neutral | +3.3% | Management presentation at Evercore healthcare conference with webcast access. |
| Nov 12 | Earnings and update | Positive | +3.5% | Q3 2025 financials plus progress in global HCV Phase 3 and HEV programs. |
| Nov 07 | Clinical data update | Positive | +0.6% | New HCV regimen data showing high SVR12 and favorable resistance profile. |
Recent AVIR news, especially clinical and data-driven updates, has typically seen modestly positive next-day price reactions.
Over the last few months, Atea advanced its HCV program and visibility with multiple milestones. In Nov 2025, Q3 results highlighted $329.3M in cash and ongoing Phase 3 trials, with shares reacting positively. New Phase 2/3 HCV data and conference appearances, including The Liver Meeting® 2025 and the Evercore Healthcare Conference, also drew positive price responses. Completion of Phase 3 C‑BEYOND enrollment in Dec 2025 further reinforced clinical progress. Today’s J.P. Morgan conference appearance continues this pattern of visibility-focused news.
Market Pulse Summary
This announcement highlights Atea’s participation at the 44th Annual J.P. Morgan Healthcare Conference, providing a platform to showcase its oral antiviral pipeline and ongoing HCV Phase 3 program. In recent months, the company reported $329.3M in cash, strong Phase 2 HCV data, and completion of key Phase 3 enrollment steps. Investors may watch for any new clinical timelines, updates on the HCV and HEV programs, and clarity on R&D spending and cash runway.
AI-generated analysis. Not financial advice.
BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, together with other members of the Atea management team, will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026 at 7:30 a.m. PT in San Francisco, CA.
A live webcast of the presentation will be available here and on the Company’s website at https://ir.ateapharma.com. An archived webcast will be available on Atea’s website for at least 90 days following the event.
About Atea Pharmaceuticals
Atea is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. Leveraging Atea’s deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleos(t)ide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of serious viral diseases. Atea plans to continue to build its pipeline of antiviral product candidates by augmenting its nucleos(t)ide platform with other classes of antivirals that may be used in combination with its nucleos(t)ide product candidates. Atea’s lead program is the regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, to treat HCV. For more information, please visit www.ateapharma.com.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include but are not limited to the anticipated date, time and content of the Company’s presentation at the conference. When used herein, words including “expects,” “may,” “will,” “anticipates,” “plans,” and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon the Company’s current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, the important factors discussed and updated from time to time under the caption “Risk Factors” in the reports the Company files with the SEC, including annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and other filings each of which are accessible on the SEC’s website at www.sec.gov. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.
Contacts
Jonae Barnes
SVP, Investor Relations and Corporate Communications
617-818-2985
barnes.jonae@ateapharma.com
Joyce Allaire
LifeSci Advisors
Jallaire@lifesciadvisors.com
FAQ
When will Atea Pharmaceuticals (AVIR) present at the J.P. Morgan Healthcare Conference?
Who will represent Atea Pharmaceuticals (AVIR) at the January 15, 2026 presentation?
How can investors watch Atea Pharmaceuticals (AVIR) present on January 15, 2026?
Will the Atea (AVIR) J.P. Morgan presentation be available after the event?
What topics will Atea Pharmaceuticals (AVIR) likely cover at the J.P. Morgan conference?
